| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma.
|
J Clin Oncol
|
2010
|
3.38
|
|
2
|
Patterns of (18)F-FDG uptake in adipose tissue and muscle: a potential source of false-positives for PET.
|
J Nucl Med
|
2003
|
2.62
|
|
3
|
Interim positron emission tomography scans in diffuse large B-cell lymphoma: an independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 study.
|
Blood
|
2009
|
2.09
|
|
4
|
Diagnostic accuracy of 18F-FDG PET in restaging patients with medullary thyroid carcinoma and elevated calcitonin levels.
|
J Nucl Med
|
2007
|
1.69
|
|
5
|
Clinical utility of 18F-FDG PET/CT in assessing the neck after concurrent chemoradiotherapy for Locoregional advanced head and neck cancer.
|
J Nucl Med
|
2008
|
1.65
|
|
6
|
18F-FDG PET/CT for the prediction and detection of local recurrence after radiofrequency ablation of malignant lung lesions.
|
J Nucl Med
|
2010
|
1.63
|
|
7
|
Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET.
|
Blood
|
2011
|
1.55
|
|
8
|
Noninvasive assessment of coronary microcirculatory function in postmenopausal women and effects of short-term and long-term estrogen administration.
|
Circulation
|
2002
|
1.55
|
|
9
|
Interim [(18)F]fluorodeoxyglucose positron emission tomography imaging in stage I-II non-bulky Hodgkin lymphoma: would using combined positron emission tomography and computed tomography criteria better predict response than each test alone?
|
Leuk Lymphoma
|
2012
|
1.54
|
|
10
|
Thymic extension in the superior mediastinum in patients with thymic hyperplasia: potential cause of false-positive findings on 18F-FDG PET/CT.
|
AJR Am J Roentgenol
|
2007
|
1.51
|
|
11
|
Fluorine-18-labeled fluoromisonidazole positron emission and computed tomography-guided intensity-modulated radiotherapy for head and neck cancer: a feasibility study.
|
Int J Radiat Oncol Biol Phys
|
2007
|
1.50
|
|
12
|
Clinical value of fluorine-18 2-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in bladder cancer.
|
J Clin Oncol
|
2010
|
1.42
|
|
13
|
Characterization of T-cell lymphomas by FDG PET/CT.
|
AJR Am J Roentgenol
|
2010
|
1.40
|
|
14
|
Prognostic value of baseline [18F] fluorodeoxyglucose positron emission tomography and 99mTc-MDP bone scan in progressing metastatic prostate cancer.
|
Clin Cancer Res
|
2010
|
1.40
|
|
15
|
Deep-inspiration breath-hold PET/CT of the thorax.
|
J Nucl Med
|
2007
|
1.39
|
|
16
|
Myocardial imaging for mitochondrial membrane potential.
|
JACC Cardiovasc Imaging
|
2012
|
1.39
|
|
17
|
Pattern of prostate-specific antigen (PSA) failure dictates the probability of a positive bone scan in patients with an increasing PSA after radical prostatectomy.
|
J Clin Oncol
|
2005
|
1.35
|
|
18
|
18F-FDG PET/CT metabolic tumor volume and total lesion glycolysis predict outcome in oropharyngeal squamous cell carcinoma.
|
J Nucl Med
|
2012
|
1.32
|
|
19
|
Pharmacokinetic assessment of the uptake of 16beta-18F-fluoro-5alpha-dihydrotestosterone (FDHT) in prostate tumors as measured by PET.
|
J Nucl Med
|
2010
|
1.27
|
|
20
|
Tumor metabolism and perfusion in head and neck squamous cell carcinoma: pretreatment multimodality imaging with 1H magnetic resonance spectroscopy, dynamic contrast-enhanced MRI, and [18F]FDG-PET.
|
Int J Radiat Oncol Biol Phys
|
2011
|
1.26
|
|
21
|
Practical approach for comparative analysis of multilesion molecular imaging using a semiautomated program for PET/CT.
|
J Nucl Med
|
2011
|
1.18
|
|
22
|
Noninvasive assessment of tumor microenvironment using dynamic contrast-enhanced magnetic resonance imaging and 18F-fluoromisonidazole positron emission tomography imaging in neck nodal metastases.
|
Int J Radiat Oncol Biol Phys
|
2009
|
1.16
|
|
23
|
Pharmacokinetic analysis of hypoxia (18)F-fluoromisonidazole dynamic PET in head and neck cancer.
|
J Nucl Med
|
2009
|
1.12
|
|
24
|
Developing imaging strategies for castration resistant prostate cancer.
|
Acta Oncol
|
2011
|
1.10
|
|
25
|
Diagnostic accuracy and prognostic value of 18F-FDG PET in Hürthle cell thyroid cancer patients.
|
J Nucl Med
|
2006
|
1.07
|
|
26
|
Clinical significance of unexplained abnormal focal FDG uptake in the abdomen during whole-body PET.
|
AJR Am J Roentgenol
|
2004
|
1.07
|
|
27
|
Split-dose technique for FDG PET/CT-guided percutaneous ablation: a method to facilitate lesion targeting and to provide immediate assessment of treatment effectiveness.
|
Radiology
|
2013
|
1.06
|
|
28
|
Hybrid imaging (SPECT/CT and PET/CT): improving therapeutic decisions.
|
Semin Nucl Med
|
2009
|
1.05
|
|
29
|
PET for staging in rhabdomyosarcoma: an evaluation of PET as an adjunct to current staging tools.
|
J Pediatr Hematol Oncol
|
2007
|
1.04
|
|
30
|
Deep-inspiration breath-hold PET/CT: clinical findings with a new technique for detection and characterization of thoracic lesions.
|
J Nucl Med
|
2007
|
1.04
|
|
31
|
Coronary artery disease after radiation therapy for Hodgkin's lymphoma: coronary CT angiography findings and calcium scores in nine asymptomatic patients.
|
AJR Am J Roentgenol
|
2008
|
1.03
|
|
32
|
Advances in positron emission tomography applications for urologic cancers.
|
Curr Opin Urol
|
2008
|
1.01
|
|
33
|
The role of imaging in the detection of prostate cancer local recurrence after radiation therapy and surgery.
|
Curr Opin Urol
|
2008
|
0.99
|
|
34
|
Molecular imaging of prostate cancer.
|
Curr Opin Urol
|
2012
|
0.98
|
|
35
|
18F-fluorodeoxyglucose positron emission tomography in the staging and prognosis of T cell lymphoma.
|
Leuk Lymphoma
|
2013
|
0.98
|
|
36
|
The effect of posttherapy 131I SPECT/CT on risk classification and management of patients with differentiated thyroid cancer.
|
J Nucl Med
|
2010
|
0.96
|
|
37
|
Prospective trial incorporating pre-/mid-treatment [18F]-misonidazole positron emission tomography for head-and-neck cancer patients undergoing concurrent chemoradiotherapy.
|
Int J Radiat Oncol Biol Phys
|
2009
|
0.94
|
|
38
|
Evaluation of romidepsin for clinical activity and radioactive iodine reuptake in radioactive iodine-refractory thyroid carcinoma.
|
Thyroid
|
2013
|
0.94
|
|
39
|
A prospective evaluation of the utility of 2-deoxy-2-[(18) F]fluoro-D-glucose positron emission tomography and computed tomography in staging locally advanced gastric cancer.
|
Cancer
|
2012
|
0.93
|
|
40
|
Target volume delineation in oropharyngeal cancer: impact of PET, MRI, and physical examination.
|
Int J Radiat Oncol Biol Phys
|
2011
|
0.93
|
|
41
|
Respiration artifacts in whole-body (18)F-FDG PET/CT studies with combined PET/CT tomographs employing spiral CT technology with 1 to 16 detector rows.
|
Eur J Nucl Med Mol Imaging
|
2005
|
0.91
|
|
42
|
Advances in imaging in the postoperative patient with a rising prostate-specific antigen level.
|
Semin Oncol
|
2003
|
0.91
|
|
43
|
Advances in oncologic imaging: update on 5 common cancers.
|
CA Cancer J Clin
|
2012
|
0.87
|
|
44
|
Pediatric bone sarcoma: diagnostic performance of ¹⁸F-FDG PET/CT versus conventional imaging for initial staging and follow-up.
|
AJR Am J Roentgenol
|
2015
|
0.83
|
|
45
|
Thyroid cancer--indications and opportunities for positron emission tomography/computed tomography imaging.
|
Semin Nucl Med
|
2011
|
0.83
|
|
46
|
Noncontrast perfusion single-photon emission CT/CT scanning: a new test for the expedited, high-accuracy diagnosis of acute pulmonary embolism.
|
Chest
|
2014
|
0.83
|
|
47
|
Evaluation of different methods of 18F-FDG-PET target volume delineation in the radiotherapy of head and neck cancer.
|
Am J Clin Oncol
|
2008
|
0.82
|
|
48
|
The anti-CD80 primatized monoclonal antibody, galiximab, is well-tolerated but has limited activity in relapsed Hodgkin lymphoma: Cancer and Leukemia Group B 50602 (Alliance).
|
Leuk Lymphoma
|
2013
|
0.81
|
|
49
|
Clinical value of combined positron emission tomography/computed tomography imaging in the interpretation of 2-deoxy-2-[F-18]fluoro-D-glucose-positron emission tomography studies in cancer patients.
|
Mol Imaging Biol
|
2005
|
0.80
|
|
50
|
[¹⁸F]FDG-positron emission tomography coregistration with computed tomography scans for radiation treatment planning of lymphoma and hematologic malignancies.
|
Int J Radiat Oncol Biol Phys
|
2010
|
0.79
|
|
51
|
The impact of systemic chemotherapy on testicular FDG activity in young men with Hodgkin's lymphoma.
|
Eur J Nucl Med Mol Imaging
|
2013
|
0.79
|
|
52
|
Incidental detection of concurrent extramedullary plasmacytoma and amyloidoma of the nasopharynx on [18F]fluorodeoxyglucose positron emission tomography/computed tomography.
|
J Clin Oncol
|
2008
|
0.79
|
|
53
|
Reporting guidance for oncologic 18F-FDG PET/CT imaging.
|
J Nucl Med
|
2013
|
0.77
|
|
54
|
Magnetic resonance imaging/positron emission tomography provides a roadmap for surgical planning and serves as a predictive biomarker in patients with recurrent gynecological cancers undergoing pelvic exenteration.
|
Int J Gynecol Cancer
|
2013
|
0.77
|
|
55
|
ABVD alone and a PET scan complete remission negates the need for radiologic surveillance in early-stage, nonbulky Hodgkin lymphoma.
|
Cancer
|
2012
|
0.77
|
|
56
|
Melanoma metastasis to the testis demonstrated with FDG PET/CT.
|
Clin Nucl Med
|
2004
|
0.76
|
|
57
|
Pilot study of PET imaging of 124I-iodoazomycin galactopyranoside (IAZGP), a putative hypoxia imaging agent, in patients with colorectal cancer and head and neck cancer.
|
EJNMMI Res
|
2013
|
0.76
|
|
58
|
Metaiodobenzylguanidine imaging comes of age. A new arrow in the prognostic quiver for heart failure patients.
|
J Am Coll Cardiol
|
2010
|
0.76
|
|
59
|
Detection and management of isolated lymph node recurrence in patients with PSA relapse.
|
Eur Urol
|
2007
|
0.75
|
|
60
|
Bladder cancer: can imaging change patient management?
|
Curr Opin Urol
|
2008
|
0.75
|
|
61
|
Predictive modeling of outcomes following definitive chemoradiotherapy for oropharyngeal cancer based on FDG-PET image characteristics.
|
Phys Med Biol
|
2017
|
0.75
|
|
62
|
Treadmill exercise inducing mild to moderate ischemia has no significant effect on skeletal muscle or cardiac 18F-FDG uptake and image quality on subsequent whole-body PET scan.
|
J Nucl Med
|
2012
|
0.75
|
|
63
|
Post-Treatment/Pre-operative PET Response Is Not an Independent Predictor of Outcomes for Patients With Gastric and GEJ Adenocarcinoma.
|
Ann Surg
|
2017
|
0.75
|